Piper Sandler analyst Brent Bracelin maintains Oracle (NYSE:ORCL) with a Neutral and raises the price target from $70 to $75.
Gilead Reports Its Veklury Retains Antiviral Activity Against Omnicron, Delta, Other Emergent COVID Variants
-- Data Supports the Continued Use of Veklury for Treatment of COVID-19 for Current SARS-CoV-2 Variants --
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ:GILD) today released data demonstrating the
